Summary
Eli Lilly & Company (LLY) filed an 8-K on March 9, 2004, primarily to furnish its audited consolidated financial statements and management's discussion and analysis for the fiscal year 2003. This information was made available at an investor conference. The company also indicated its intention to file its full Form 10-K for 2003 and mail its annual report to shareholders and proxy statement around March 12, 2004. This filing provides investors with early access to key financial performance data and management's perspective on the company's results for 2003, ahead of the formal 10-K submission. While the 8-K doesn't introduce new material events, it serves as a crucial update for stakeholders seeking to assess the company's financial health and strategic outlook based on its audited performance.
Key Highlights
- 1Eli Lilly furnished its audited consolidated financial statements for 2003.
- 2Management's Discussion and Analysis (MD&A) for 2003 was also provided.
- 3The financial information was presented at an investor conference.
- 4The company planned to file its Form 10-K for 2003 on or about March 12, 2004.
- 5The 2003 annual report to shareholders and proxy statement were scheduled for mailing around March 12, 2004.
- 6This 8-K serves as a Regulation FD disclosure, making information available to the public concurrently.